ClinicalTrials.gg
CompletedNCT04385368MERMAID-1Updated Aug 30, 2024Results posted

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

A Phase 3 interventional study of Durvalumab + SoC chemotherapy and Placebo + SoC chemotherapy in Carcinoma, Non-Small-Cell Lung, sponsored by AstraZeneca. Completed at 141 sites in 33 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-08-30.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
42nd of 94
89 · median 74
Started
2020
with 13 others
Phase 3
17 of 94
3 open now
Registered
60th of 94
by date
Lead sponsor
25 of 94
AstraZeneca

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 42nd largest by enrollment, is one of 14 that started in 2020, is one of 17 in phase 3, and was the 60th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery

Read the detailed description

Patients who have no evidence of disease recurrence confirmed by CT and/or MRI and are confirmed to meet all eligibility criteria will be randomized 1:1 to durvalumab + Standard of care (SoC) chemotherapy or placebo + Standard of care (SoC) chemotherapy arm.

The primary objective of this study is to assess the efficacy of durvalumab +SoC chemotherapy compared to placebo+ SoC chemotherapy as measured by DFS in all patients.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • NCSLC
  • Double-blind
  • PD-L1
  • MEDI4736
  • Durvalumab
  • DFS
  • OS
  • MRD+
  • MRD-
  • Completely Resected Lung Cancer
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must be capable of giving signed , which includes a mandatory genetic informed consent and compliance with the requirements and restrictions listed in the informed consent forms (ICFs) and in this protocol. Provision of signed and dated, written ICFs must occur prior to any mandatory study-specific procedures, sampling, and analyses.

In addition to ICF1 and ICF2, patients will provide signed and dated written optional genetic informed consent prior to collection of a sample for optional genetic analysis at the time of second screening (Table 2). This is different from the genetic samples and testing covered by ICF1, which are mandatory for participation in this study.

Criteria and procedures initiated with the signing of ICF1

  1. ICF1 must be signed and dated prior to any study procedures and prior to the planned surgical resection of the primary NSCLC, with the exceptions noted below. This consent will cover the study-specific first screening procedures outlined in Table 1.

    Exception: Patients will be permitted to sign ICF1 up to Week 3 (Day 21) postsurgery. Patients identified after Week 3 post-surgery but prior to Week 5 (Day 35) post-surgery may be allowed to sign ICF1 depending on the outcome of the discussion with the study physician. In these cases, a whole blood sample and resected tumor tissue must be collected and sent to the diagnostic lab as soon as possible after ICF1 is signed for development of the personalized panel. A plasma sample must still be collected at Week 3-5 (Day 21-35) post-surgery, even if creation of the personalized panel for MRD detection is delayed.

    Age

  2. Age ≥18 years at the time of screening. Sex
  3. Male and/or female. Type of patient and disease characteristics
  4. Individuals who have diagnosis of confirmed NSCLC (WHO 2015 classification) with resectable (stage II-III) disease (according to IASLC Staging Manual in Thoracic Oncology v8.0). Select (ie, T3N2 or T4N2) stage IIIB patients will be eligible, provided that they are upstaged to T3N2 or T4N2 based on confirmed pathology. Patients who are staged asT3N2 or T4N2 prior to surgery are not eligible.
  5. A contrast-enhanced CT or MRI scan of the chest must have been done for surgical planning prior to surgery. It is recommended that patients undergo combined FDG-PET (18F-Fluoro-deoxyglucose positron emission tomography) and CT scan (contrastenhanced or low-dose CT component) in order to rule out detectable extrathoracic, extracranial and to assess for potential mediastinal lymph node involvement prior to surgery. In the absence of pre-operative FDG-PET CT imaging, pre-operative contrast-enhanced CT imaging or MRI scan must cover liver and adrenal glands. If only CT is available, or FDG-PET reveals suspicious lymph node mediastinal involvement, it is recommended that invasive pre-operative mediastinal staging is performed according to the algorithm of the European Society of Thoracic Surgeons guidelines (algorithm to follow for primary mediastinal staging if only pre-operative CT is available [De Leyn et al 2007], algorithm to follow for primary mediastinal staging when PET-CT is available [De Leyn et al 2014]). It is preferred that imaging occurs within 6 weeks prior to surgery. Brain MRI (preferred) or brain CT with IV contrast is required for complete staging of the tumor.
  6. Complete resection of the primary NSCLC is mandatory. The primary tumor must be deemed resectable by a multidisciplinary evaluation that must include a thoracic surgeon certified or trained according to local standards and who performs lung cancer surgery as a significant part of their practice. Surgical resection of the primary NSCLC can occur by open thoracotomy or by video-assisted thoracic surgery (VATS) and resection can be achieved by segmentectomy, lobectomy, sleeve resection, bilobectomy, or pneumonectomy. Patients undergoing wedge resection are not eligible for this study. Note: Patients undergoing segmentectomy must have tumors less than 2 cm in maximum diameter. Where a resection has been extended by means of a wedge resection of an adjacent lobe to ensure complete resection of a tumor at or crossing a fissure between lobes, this is acceptable if surgical margins are clear of disease. Where the resection of a second tumor nodule (eg, a T4 lesion) is undertaken by means of a wedge resection of a separate lobe, then the patient is not eligible.

    At a minimum, the following parameters should be met for a tumor to be declared completely resected:

    1. The surgeon performing the resection should remove all gross disease by the end of surgery. All surgical margins of resection must be macroscopically negative for tumor.
    2. Pathology and/or operative reports must include the examination of at least 2 different mediastinal lymph node (N2) levels, one of which is the subcarinal node-group (level 7) and the second of which is lobe-specific (defined below).

      Note: In the uncommon clinical situation where the surgeon thoroughly examines a mediastinal lymph node level and does not find any lymph nodes, that mediastinal lymph node level may be counted among the minimum 2 required levels. However, the surgeon must clearly document in the operative report or in a separate written statement that the lymph node level was explored and no lymph nodes were present. Normal appearing lymph nodes, if present, must be biopsied or removed. Exploration of nodes must clearly be documented in medical file if not recorded in operative report.

      Note: Lobe-specific lymph node stations are classified based on the location of the primary tumor as follows (based on IASLC 2009 lymph node map terminology [Rusch et al 2009]): Stations 2R and 4R for right upper lobe or middle lobe tumors, stations 4L, 5, and 6 for left upper lobe tumors, stations 8 and 9 for lower lobe tumors of both sides (Adachi et al 2017, Rami-Porta et al 2005).

    3. No extracapsular nodal extension of the tumor is observed in resected mediastinal N2 lymph nodes.

    Note: Extracapsular nodal extension in resected N1 nodes is permitted. Note: The highest mediastinal node resected can be positive for . Note: Carcinoma-in-situ can be present at the bronchial margin.

  7. All patients who enrol in the study prior to surgery must have a pre-surgical plasma sample collected for MRD evaluation. Patients will not be excluded from randomization based on the results of analysing the pre-surgical plasma samples.

    The following criteria must be met prior to signing ICF2:

  8. Confirmation of suitable samples of resected tumor tissue and whole blood for WES of tumor and germline DNA, respectively, and creation of Sponsor-approved personalized panel for MRD detection. Tumor tissue and whole blood samples must be provided to the diagnostic laboratory for development of the personalized panel as soon as possible.

    Germline sequencing of whole blood is mandatory. Note: If a patient's tumor has less than the requisite 50 tumor-specific variants, a panel cannot be built and the patient will no longer be able to participate in the study.

  9. Established MRD status (MRD+ or MRD-) based on Sponsor-approved personalized assay of a plasma sample collected at Week 3-5 (Day 21-35) post-surgery.
  10. Known tumor status determined at a central reference laboratory testing service using a validated Ventana SP263 PD-L1 immunohistochemistry (IHC) assay prior randomization. Patients with unknown PD-L1 status are not eligible for the study.

    Criteria and procedures initiated with the signing of ICF2

  11. Post-operative CT scan of the chest (including liver and adrenal glands) performed within 28 days + 7 days prior to randomization. If clinically indicated, additional scans (such as brain MRI [preferred] or brain CT with IV contrast) should be performed to confirm no evidence of metastasis.
  12. ICF2 must be signed and dated after MRD status is determined and prior to initiation of any study-specific procedures, sampling, and analyses outlined in SoAs in Table 2 and Table 3. Randomization must occur within the 12 weeks (+ 7 days) following surgery.
  13. WHO/ (ECOG) performance status of 0 or 1.
  14. Complete postoperative wound healing must have occurred prior to randomization; patients must have recovered from all acute, reversible toxic effects from prior treatments (excluding alopecia) that could potentially adversely impact further administration of durvalumab/placebo or chemotherapy according to the Investigator's judgment.
  15. Eligible to tolerate 4 cycles of platinum-based chemotherapy
  16. Adequate organ and marrow function as described in the protocol. 17 Must have a of at least 12 weeks Weight 18 Body weight >30 kg

Exclusion criteria

Exclusion criteria:

Diagnostic assessments

  1. Post-operative imaging demonstrating unequivocal evidence of disease recurrence or tissue -proven disease recurrence. In the event of lymphadenopathy on imaging that would lead to exclusion, histopathological confirmation of lymph node should be obtained prior to excluding a patient from the study. If pathological confirmation of lymph-node metastasis is not technically feasible and imaging appearance are deemed unequivocal for relapse, the patient will be excluded.
  2. EGFR-mutant and/or ALK-translocation-positive, as assessed either from a pre-surgical biopsy sample (preferred) or the resected tumor tissue (if biopsy was not evaluable or available). Any of the following scenarios are acceptable for this study:

    Where EGFR/ALK results are obtained from a pre-surgical tissue biopsy as part of standard local practice, the patient must be confirmed EGFR/ALK wild-type prior to enrolling in the study.

    Results obtained from testing the patient's primary tumor tissue during screening for another AstraZeneca study may be used in this study.

    Results from local testing of a pre-surgical biopsy. All local EGFR/ALK testing performed locally must be performed using a well-validated, local regulatory-approved test. EGFR/ALK may be tested centrally if local testing is unavailable. Patients will still be allowed to continue with first screening procedures while testing is ongoing but will not be able to continue into second screening if their tumor tests positive for EGFR mutations and/or ALK translocations.

  3. Mixed small cell and NSCLC histology.
  4. Require re-resection or are deemed to have unresectable NSCLC by a multidisciplinary evaluation that must include a thoracic surgeon who performs lung cancer surgery as a significant part of their practice.
  5. Patients who are candidates to undergo only wedge resections. Medical conditions
  6. History of allogeneic organ or bone marrow transplantation.
  7. Non-leukocyte-depleted whole blood transfusion within 120 days of genetic sample collection. Note: This exclusion criterion only relates to whole blood and does not include other blood products (eg, packed red blood cells).
  8. Active or prior documented or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:

    • Patients with vitiligo or alopecia
    • Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement
    • Any chronic skin condition that does not require systemic therapy
    • Patients without active disease in the last 5 years may be included but only after consultation with the Study Physician
    • Patients with celiac disease controlled by diet alone
  9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active ILD, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring AEs, or compromise the ability of the patient to give written .
  10. History of another primary , except for

    • Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    • Adequately treated carcinoma-in-situ without evidence of disease
  11. History of active primary immunodeficiency
  12. Active infection, including tuberculosis (clinical evaluation that includes clinical history, physical examination, and radiographic findings, and tuberculosis testing in line with local practice), (HBV; known positive HBV surface antigen [HBsAg] result), (HCV), or infection (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  13. Known allergy or to any of the IPs or any of the IP .
  14. Any medical to treatment with platinum-based doublet chemotherapy as listed in the local labeling.

    Prior/concomitant therapy

  15. Received any prior therapy for NSCLC or any prior exposure to durvalumab.
  16. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) is acceptable.
  17. Radiotherapy treatment for NSCLC in the neoadjuvant setting. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of IP.
  18. Receipt of within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine while receiving IP and up to 30 days after the last dose of IP.
  19. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.
  20. Current or prior use of medication within 14 days before the first dose of durvalumab/placebo. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical , or local steroid injections (eg, intra-articular injection)
    • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
    • Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication) Prior/concurrent clinical study experience
  21. Participation in another clinical study with an IP administered since completion of surgery.
  22. Previous IP assignment in the present study.
  23. Concurrent enrollment in another clinical study, unless it is an observational (noninterventional) clinical study, or during the follow-up period of an interventional study.
  24. Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment group assignment.

    Other exclusions

  25. Patients who are never-smokers; defined as no more than 100 cigarettes or its equivalent in his/her lifetime.
  26. Female patients who are pregnant or breastfeeding or male or female patients of who are not willing to employ effective from screening to 90 days after the last dose of durvalumab/placebo.
  27. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Durvalumab + SoC chemotherapy

    Intravenous administration of Experimental and Standard of Care Therapy

    Drug: Durvalumab + SoC chemotherapy

  • Placebo comparator
    Placebo + SoC chemotherapy

    Intravenous administration of Placebo and Standard of Care Therapy

    Other: Placebo + SoC chemotherapy

Interventions

  • DrugDurvalumab + SoC chemotherapy

    Drug page: Durvalumab

    Experimental Treatment

    Also known as: MEDI4736

  • OtherPlacebo + SoC chemotherapy

    Placebo Comparator

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Disease-free Survival (DFS) in FAS (Using Investigator Assessments According to Response Evaluation Criteria in Solid Tumors 1.1 [RECIST 1.1])

    DFS was defined as the time from the date of randomization until either of the following events, whichever occurred first: disease recurrence using Investigator RECIST 1.1 assessments (i.e., local or regional recurrence, distant recurrence, second primary NSCLC) or death from any cause.

    Time frame: Every 12 weeks (q12w) ± 1 week until appearance of RECIST 1.1-defined disease recurrence or until primary DFS analysis, up to 33.28 months

Secondary outcomes

  1. DFS in Minimal Residual Disease-positive (MRD+) Analysis Set (Using Investigator Assessments According to RECIST 1.1)

    DFS was defined as the time from the date of randomization until either of the following events, whichever occurred first: disease recurrence using Investigator RECIST 1.1 assessments (i.e., local or regional recurrence, distant recurrence, second primary NSCLC) or death from any cause.

    Time frame: Every 12 weeks (q12w) ± 1 week until appearance of RECIST 1.1-defined disease recurrence or until primary DFS analysis, up to 33.28 months

  2. OS in FAS

    OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.

    Time frame: From the date of randomization until death due to any cause, up to 35 months

  3. Overall Survival (OS) in MRD+ Analysis Set

    OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.

    Time frame: From the date of randomization until death due to any cause, up to 35 months

07

Results

Posted Aug 30, 2024
Limitations and caveats
The sponsor closed enrollment early due to the changes in the treatment landscape. Interpretation of the efficacy results is inconclusive due to the small sample size, resulting in wide confidence intervals, and limited duration of follow-up. The overall safety findings remained consistent with the known safety profiles of durvalumab and SoC chemotherapy. No new safety concerns were identified in this study.

Participant flow

This Phase III, multicenter, randomized, double-blind, placebo-controlled study was conducted in participants with completely resected stage II to III non-small cell lung cancer (NSCLC) at 63 sites across 25 countries from 17 July 2020 to 31 August 2023.

Participant flow — Overall Study
MilestoneDurvalumab + SoCPlacebo + SoC
Started4544
Completed3336
Not completed128
Withdrew: Death55
Withdrew: Physician decision30
Withdrew: Withdrawal by subject43

Outcome measures

PrimaryDisease-free Survival (DFS) in FAS (Using Investigator Assessments According to Response Evaluation Criteria in Solid Tumors 1.1 [RECIST 1.1])

DFS was defined as the time from the date of randomization until either of the following events, whichever occurred first: disease recurrence using Investigator RECIST 1.1 assessments (i.e., local or regional recurrence, distant recurrence, second primary NSCLC) or death from any cause.

Time frame:
Every 12 weeks (q12w) ± 1 week until appearance of RECIST 1.1-defined disease recurrence or until primary DFS analysis, up to 33.28 months
Reported as:
Median · months
Disease-free Survival (DFS) in FAS (Using Investigator Assessments According to Response Evaluation Criteria in Solid Tumors 1.1 [RECIST 1.1])
monthsDurvalumab + SoCPlacebo + SoC
Disease-free Survival (DFS) in FAS (Using Investigator Assessments According to Response Evaluation Criteria in Solid Tumors 1.1 [RECIST 1.1])NA (14.062 to NA)NA (21.914 to NA)
SecondaryDFS in Minimal Residual Disease-positive (MRD+) Analysis Set (Using Investigator Assessments According to RECIST 1.1)

DFS was defined as the time from the date of randomization until either of the following events, whichever occurred first: disease recurrence using Investigator RECIST 1.1 assessments (i.e., local or regional recurrence, distant recurrence, second primary NSCLC) or death from any cause.

Time frame:
Every 12 weeks (q12w) ± 1 week until appearance of RECIST 1.1-defined disease recurrence or until primary DFS analysis, up to 33.28 months
Reported as:
Median · months
DFS in Minimal Residual Disease-positive (MRD+) Analysis Set (Using Investigator Assessments According to RECIST 1.1)
monthsDurvalumab + SoCPlacebo + SoC
DFS in Minimal Residual Disease-positive (MRD+) Analysis Set (Using Investigator Assessments According to RECIST 1.1)16.7 (2.661 to NA)NA (5.585 to NA)
SecondaryOS in FAS

OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.

Time frame:
From the date of randomization until death due to any cause, up to 35 months
Reported as:
Median · months
OS in FAS
monthsDurvalumab + SoCPlacebo + SoC
OS in FASNA (NA to NA)NA (NA to NA)
SecondaryOverall Survival (OS) in MRD+ Analysis Set

OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.

Time frame:
From the date of randomization until death due to any cause, up to 35 months
Reported as:
Median · months
Overall Survival (OS) in MRD+ Analysis Set
monthsDurvalumab + SoCPlacebo + SoC
Overall Survival (OS) in MRD+ Analysis SetNA (9.331 to NA)NA (13.372 to NA)

Adverse events

Collected over Treatment emergent adverse events (TEAEs) were collected from first dose of study treatment up to 90 days after the last dose of study treatment, 19.1 months. All-cause mortality was assessed from the start of randomization up to completion of study, 35 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab + SoC6/45 (13.3%)14/45 (31.1%)43/45 (95.6%)
Placebo + SoC5/44 (11.4%)10/44 (22.7%)44/44 (100%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventDurvalumab + SoCPlacebo + SoC
PneumoniaInfections and infestations3/451/44
ColitisGastrointestinal disorders3/450/44
Acute kidney injuryRenal and urinary disorders0/452/44
COVID-19Infections and infestations0/452/44
AnaemiaBlood and lymphatic system disorders2/450/44
Infusion related reactionInjury, poisoning and procedural complications0/451/44
Cardiac arrestCardiac disorders0/451/44
Loss of consciousnessNervous system disorders0/451/44
AzotaemiaRenal and urinary disorders0/451/44
Pulmonary artery thrombosisRespiratory, thoracic and mediastinal disorders0/451/44
Most frequent other events
Showing 10 of 52
Most frequent other events
EventDurvalumab + SoCPlacebo + SoC
NauseaGastrointestinal disorders19/4518/44
ConstipationGastrointestinal disorders12/4517/44
AnaemiaBlood and lymphatic system disorders15/4512/44
FatigueGeneral disorders15/4512/44
AlopeciaSkin and subcutaneous tissue disorders13/459/44
DiarrhoeaGastrointestinal disorders11/457/44
Decreased appetiteMetabolism and nutrition disorders9/457/44
ArthralgiaMusculoskeletal and connective tissue disorders7/458/44
Neutrophil count decreasedInvestigations8/455/44
HeadacheNervous system disorders8/454/44

Baseline characteristics

The Full analysis set (FAS) included all randomized participants.

Age, Continuous
Age, Continuous(years)Durvalumab + SoCPlacebo + SoCTotal
Mean65.5 ± 8.7864.5 ± 7.3765.0 ± 8.08
Sex: Female, Male
Sex: Female, Male(Participants)Durvalumab + SoCPlacebo + SoCTotal
Female171532
Male282957
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Durvalumab + SoCPlacebo + SoCTotal
American Indian or Alaska Native011
Asian91827
White352257
Not reported134
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Durvalumab + SoCPlacebo + SoCTotal
Hispanic or Latino415
Not Hispanic or Latino404383
Missing101
08

Study locations

141 sites
  • Research Site
    Birmingham, Alabama 35294, United States
  • Research Site
    Long Beach, California 90806, United States
  • Research Site
    Santa Rosa, California 95403, United States
  • Research Site
    West Hollywood, California 90048, United States
  • Research Site
    Miami, Florida 33136, United States
  • Research Site
    Silver Spring, Maryland 20910, United States
  • Research Site
    Minneapolis, Minnesota 55407, United States
  • Research Site
    Lincoln, Nebraska 68510, United States
  • Research Site
    Albuquerque, New Mexico 87131, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Spartanburg, South Carolina 29303, United States
  • Research Site
    Sioux Falls, South Dakota 57105, United States
  • Research Site
    Houston, Texas 77090, United States
  • Research Site
    Seattle, Washington 98108-1532, United States
  • Research Site
    Rosario, S2000CVB, Argentina
  • Research Site
    Camperdown, 2050, Australia
  • Research Site
    St Leonards, 2065, Australia
  • Research Site
    Aalst, 9300, Belgium
  • Research Site
    Bruxelles, 1200, Belgium
  • Research Site
    Hasselt, 3500, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Roeselare, 8800, Belgium
  • Research Site
    Belo Horizonte, 30110-022, Brazil
  • Research Site
    Blumenau, 89010-340, Brazil
  • Research Site
    Fortaleza, 60336-045, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 04501-000, Brazil
  • Research Site
    Vitoria, 29043-260, Brazil
  • Research Site
    Panagyurishte, 4500, Bulgaria
  • Research Site
    Sofia, 1113, Bulgaria
  • Research Site
    Sofia, 1618, Bulgaria
  • Research Site
    Victoria, British Columbia V8R 6V5, Canada
  • Research Site
    Saint John, New Brunswick E2L 4L2, Canada
  • Research Site
    Kingston, Ontario K7L 2V7, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Olomouc, 77900, Czechia
  • Research Site
    Ostrava, 703 00, Czechia
  • Research Site
    Praha 2, 128 08, Czechia
  • Research Site
    Praha, 140 59, Czechia
  • Research Site
    Copenhagen, 2100, Denmark
  • Research Site
    Odense C, 5000, Denmark
  • Research Site
    Bordeaux, 33000, France
  • Research Site
    Marseille, 13915, France
  • Research Site
    Saint Herblain, 44805, France
  • Research Site
    Strasbourg Cedex, 67091, France
  • Research Site
    Toulouse, 31000, France
  • Research Site
    Villejuif Cedex, 94805, France
  • Research Site
    Esslingen, 73730, Germany
  • Research Site
    Gauting, 82131, Germany
  • Research Site
    Regensburg, 93049, Germany
  • Research Site
    Athens, 11526, Greece
  • Research Site
    Athens, 11527, Greece
  • Research Site
    Heraklion, 711 11, Greece
  • Research Site
    Holargos, Athens, 155 62, Greece
  • Research Site
    Thessaloniki, 54645, Greece
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    Budapest, 1121, Hungary
  • Research Site
    Gyöngyös - Mátraháza, 3200, Hungary
  • Research Site
    Győr, 9024, Hungary
  • Research Site
    Szolnok, 5004, Hungary
  • Research Site
    Törökbálint, 2045, Hungary
  • Research Site
    Bengaluru, 560099, India
  • Research Site
    Delhi, 110029, India
  • Research Site
    Mohali, 160055, India
  • Research Site
    Haifa, 3109601, Israel
  • Research Site
    Kfar Saba, 95847, Israel
  • Research Site
    Petah Tikva, 49100, Israel
  • Research Site
    Ramat Gan, 5265601, Israel
  • Research Site
    Meldola, 47014, Italy
  • Research Site
    Orbassano, 10043, Italy
  • Research Site
    Roma, 00144, Italy
  • Research Site
    Akashi-shi, 673-8558, Japan
  • Research Site
    Bunkyo-ku, 113-8677, Japan
  • Research Site
    Hiroshima-shi, 734-8551, Japan
  • Research Site
    Kashiwa, 277-8577, Japan
  • Research Site
    Koto-ku, 135-8550, Japan
  • Research Site
    Nagoya-shi, 464-8681, Japan
  • Research Site
    Nagoya-shi, 466-8560, Japan
  • Research Site
    Osaka-shi, 534-0021, Japan
  • Research Site
    Osaka-shi, 541-8567, Japan
  • Research Site
    Sendai-shi, 980-0873, Japan
  • Research Site
    Sunto-gun, 411-8777, Japan
  • Research Site
    Yokohama-shi, 241-8515, Japan
  • Research Site
    Cheongju-si, 28644, Korea, Republic of
  • Research Site
    Seoul, 05505, Korea, Republic of
  • Research Site
    Seoul, 06351, Korea, Republic of
  • Research Site
    Seoul, 06591, Korea, Republic of
  • Research Site
    Suwon, 442-723, Korea, Republic of
  • Research Site
    Culiacan, 80040, Mexico
  • Research Site
    Mexico, 01710, Mexico
  • Research Site
    Breda, 4818 CK, Netherlands
  • Research Site
    Maastricht, 6202 AZ, Netherlands
  • Research Site
    Zwolle, 8025 AB, Netherlands
  • Research Site
    Lima, Lima 32, Peru
  • Research Site
    Bydgoszcz, 85-796, Poland
  • Research Site
    Gdańsk, 80-214, Poland
  • Research Site
    Tomaszów Mazowiecki, 97-200, Poland
  • Research Site
    Warszawa, 02-781, Poland

Showing the first 100 of 141 sites across 33 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Aug 2023, 37 months.

Results were first posted in Aug 2024, 11 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 37 months is close to that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2020
First posted
May 12, 2020
StartActual
Jul 17, 2020
Primary completionActual
Aug 31, 2023
CompletionActual
Aug 31, 2023
Results first posted
Aug 30, 2024
Last update
Aug 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04385368
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 12, 2020
Start date
Jul 17, 2020
Primary completion
Aug 31, 2023
Completion
Aug 31, 2023
Results posted
Aug 30, 2024
Last update
Aug 30, 2024

Study contacts

Solange Peters
principal investigator · Centre Hospitalier Universitaire Vaudois (CHUV)
Charles Swanton
principal investigator · Francis Crick Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion